BNP Paribas Arbitrage SA boosted its holdings in shares of DURECT Co. (NASDAQ:DRRX) by 1,420.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,545 shares of the specialty pharmaceutical company’s stock after purchasing an additional 39,746 shares during the period. BNP Paribas Arbitrage SA’s holdings in DURECT were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its position in DURECT by 2.4% during the third quarter. Vanguard Group Inc. now owns 7,097,974 shares of the specialty pharmaceutical company’s stock valued at $7,808,000 after purchasing an additional 163,148 shares during the period. Geode Capital Management LLC lifted its position in DURECT by 4.2% during the fourth quarter. Geode Capital Management LLC now owns 1,700,377 shares of the specialty pharmaceutical company’s stock valued at $821,000 after purchasing an additional 68,266 shares during the period. Deutsche Bank AG lifted its position in DURECT by 19.1% during the fourth quarter. Deutsche Bank AG now owns 840,772 shares of the specialty pharmaceutical company’s stock valued at $405,000 after purchasing an additional 134,548 shares during the period. Raymond James & Associates acquired a new position in DURECT during the fourth quarter valued at $171,000. Finally, Rhumbline Advisers lifted its position in DURECT by 44.6% during the fourth quarter. Rhumbline Advisers now owns 204,285 shares of the specialty pharmaceutical company’s stock valued at $99,000 after purchasing an additional 62,985 shares during the period. Institutional investors own 44.40% of the company’s stock.
Separately, HC Wainwright restated a “buy” rating and set a $3.50 target price on shares of DURECT in a research report on Thursday, May 9th.
In other news, Director Jon S. Saxe acquired 40,400 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was acquired at an average price of $0.70 per share, for a total transaction of $28,280.00. Following the completion of the transaction, the director now owns 27,810 shares in the company, valued at approximately $19,467. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders acquired 95,400 shares of company stock valued at $60,930. Insiders own 10.20% of the company’s stock.
Shares of DURECT stock opened at $0.52 on Friday. The stock has a market capitalization of $85.14 million, a price-to-earnings ratio of -3.26 and a beta of 1.89. DURECT Co. has a fifty-two week low of $0.46 and a fifty-two week high of $2.24. The company has a debt-to-equity ratio of 1.82, a current ratio of 3.74 and a quick ratio of 3.39.
DURECT (NASDAQ:DRRX) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $3.50 million. DURECT had a negative net margin of 125.76% and a negative return on equity of 108.92%. On average, sell-side analysts predict that DURECT Co. will post -0.19 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2019/06/15/bnp-paribas-arbitrage-sa-boosts-position-in-durect-co-nasdaqdrrx.html.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.
Featured Story: Bollinger Bands
Want to see what other hedge funds are holding DRRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DURECT Co. (NASDAQ:DRRX).
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.